| 产品名称 |
Recombinant Human GIPR N-ECD (C-Fc) |
| 英文名称 |
GIPR (Arg22-Gln138) |
| 纯度 |
Greater than 95% as determined by reducing SDS-PAGE |
| 内毒素 |
<1 EU/µg as determined by LAL test. |
| 蛋白构建 |
Recombinant Human Gastric inhibitory polypeptide receptor is produced by our Mammalian expression system and the target gene encoding Arg22-Gln138 is expressed with a human IgG1 Fc tag at the C-terminus. |
| Accession |
P48546 |
| 表达宿主 |
Human Cells |
| 种属 |
Human |
| 预测分子量 |
40.3 kDa |
| 制剂 |
Supplied as a 0.2 μm filtered solution of PBS, pH7.4. |
| 运输方式 |
The product is shipped on dry ice/polar packs.Upon receipt, store it immediately at the temperature listed below. |
| 稳定性&储存 |
Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening.Please minimize freeze-thaw cycles. |
| 复溶 |
| 分子别名 |
| Gastric inhibitory polypeptide receptor; GIP-R; Glucose-dependent insulinotropic polypeptide receptor; GIPR |
| 背景介绍 |
| GIP receptor (GIPR) belongs to the G-protein coupled receptor family, activating adenylate cyclase and increasing levels of intracellular cyclic adenosine monophosphate (cAMP) in pancreatic b cells, thereby stimulating insulin section glucosedependently. New discoveries of GIP receptor (GIPR) biology in adipose tissue, as well as findings that co-agonists for the glucagon-like peptide-1 receptor (GLP-1R) and GIPR induce greater weight loss than that seen with GLP-1R agonists alone, has led to continued interest in manipulating GIPR activity for the treatment of obesity/type 2 diabetes mellitus (T2DM). |
注意事项
本司产品仅用于科研，不用于临床诊断和治疗
